The earnings call reflects a positive trajectory for Apellis with significant achievements such as FDA approval for EMPAVELI's expanded label, continued market leadership of SYFOVRE, and strong financial positioning. However, challenges such as high free goods usage affecting revenue and ongoing funding shortages for patient assistance programs present areas of concern.

Company Guidance

During the second quarter of 2025, Apellis Pharmaceuticals reported total revenue of $178 million, including $151 million from SYFOVRE sales, which experienced a 6% increase in demand quarter-over-quarter. SYFOVRE maintained its market leadership in geographic atrophy (GA) with over 60% market share and 55% of new patient starts. However, revenue was impacted by approximately $13 million due to high utilization of free goods related to funding shortages in co-pay assistance programs. EMPAVELI generated $21 million in revenue, marking a 5% increase quarter-over-quarter, with patient compliance rates at 97%. The company anticipates meaningful revenue from EMPAVELI's new label expansion for C3G and primary IC-MPGN in the fourth quarter. Apellis ended the quarter with $370 million in cash and cash equivalents, bolstered by a $275 million upfront payment from a capped royalty agreement with Sobi. Operating expenses were $212 million, and the company expects these to remain consistent year-over-year.

FDA Approval for EMPAVELI Label Expansion

EMPAVELI received FDA approval for label expansion to treat patients 12 years and older with C3 myelopathy or primary immune complex membranoproliferative glomerulonephritis, marking the third FDA approval in four years for Apellis.

SYFOVRE Market Leadership

SYFOVRE continues to lead the geographic atrophy market with over 60% market share and 55% of new patient starts during the quarter.

Strong Financial Position

Apellis ended the quarter with $370 million in cash and cash equivalents and expects to reach sustainable profitability with the $275 million upfront payment from the Sobi royalty purchase agreement.

EMPAVELI Revenue Growth

EMPAVELI revenue in the second quarter reached $21 million, a 5% increase quarter-over-quarter with a patient compliance rate of 97%.

Apellis Pharmaceuticals (APLS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

APLS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 10, 2025	2025 (Q3)	1.59 / -	-0.46	―	―	―
Jul 31, 2025	2025 (Q2)	-0.47 / -0.33	-0.3	-10.00% (-0.03)
May 07, 2025	2025 (Q1)	-0.34 / -0.74	-0.54	-37.04% (-0.20)
Feb 28, 2025	2024 (Q4)	-0.37 / -0.29	-0.73	60.27% (+0.44)
Nov 05, 2024	2024 (Q3)	-0.29 / -0.46	-1.17	60.68% (+0.71)
Aug 01, 2024	2024 (Q2)	-0.31 / -0.30	-1.02	70.59% (+0.72)
May 07, 2024	2024 (Q1)	-0.48 / -0.54	-1.56	65.38% (+1.02)
Feb 27, 2024	2023 (Q4)	-0.73 / -0.73	-1.5	51.33% (+0.77)
Nov 01, 2023	2023 (Q3)	-0.99 / -1.17	-1.75	33.14% (+0.58)
Jul 31, 2023	2023 (Q2)	-1.36 / -1.02	-1.46	30.14% (+0.44)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

APLS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$19.00	$22.34	+17.58%
May 07, 2025	$19.12	$17.99	-5.91%
Feb 28, 2025	$26.00	$25.15	-3.27%
Nov 05, 2024	$28.56	$28.08	-1.68%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Apellis Pharmaceuticals Inc (APLS) report earnings?

Apellis Pharmaceuticals Inc (APLS) is schdueled to report earning on Nov 10, 2025, After Close (Confirmed).

What is Apellis Pharmaceuticals Inc (APLS) earnings time?

Apellis Pharmaceuticals Inc (APLS) earnings time is at Nov 10, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is APLS EPS forecast?

APLS EPS forecast for the fiscal quarter 2025 (Q3) is 1.59.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing